{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:50:47Z","timestamp":1777481447382,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Buthus martensi<\/jats:italic>\n                      Karsch (BmK) CT, a kind of scorpion toxin peptide, was found to inhibit glioma cell proliferation in previous researches.\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT may have more inhibition effect and could be used as a glioma cell-targeted therapy and imaging agent. The purpose of this study was to investigate whether\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT could specifically conjugate with C6 glioma cell and induce glioma cell inhibition\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      After cloning, expression, and purification, BmK CT was labeled with\n                      <jats:sup>131<\/jats:sup>\n                      I by indirect labeling (Bolton\u2013Hunter method). The cell conjugation experiment was performed to investigate the connection between the reciprocal of cell conjugation rate and the reciprocal of cell count. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method and flow cytometry were used to detect the inhibition effect of BmK CT and\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT on glioma cell proliferation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT was successfully prepared with the overall yield of 34.5%. The cell conjugation experiment indicated that\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT could specifically conjugate with C6 cells. MTT tests indicated that both BmK CT and\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT could inhibit C6 growth. The ability of\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT to inhibit cell growth is superior to that of BmK CT. The inhibitory rate (IR) of glioma cells was 60.5% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01) at the concentration of 2\u2009\u03bcg\/mL with BmK CT. And the IR was 71.2% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01) at the radioactivity concentration of 50\u2009\u03bcCi\/mL (concentration was much lower than 2\u2009\u03bcg\/mL) with\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT. BmK CT could block the C6 glioma cell cycle in the G0\/G1 stage.\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT blocked the cell cycle in the S stage (the proportions of C6 in the S, G0\/G1, and G2\/M phases were 24.5%\u2009\u00b1\u20090.4% vs. 44.0%\u2009\u00b1\u20092.3%, 63.9%\u2009\u00b1\u20090.6% vs. 51.8%\u2009\u00b1\u20091.6%, and 11.6%\u2009\u00b1\u20091.0% vs. 4.3\u2009\u00b1\u20090.7% [\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05], respectively, at an initial radioactivity concentration of 50\u2009\u03bcCi\/mL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      On the basis of cytology experiments, it was found that\n                      <jats:sup>131<\/jats:sup>\n                      I-BmK CT could specifically conjugate with C6 glioma cell and inhibit cell growth. Hence, it may be used as a glioma-targeted agent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2009.0704","type":"journal-article","created":{"date-parts":[[2010,6,25]],"date-time":"2010-06-25T13:44:07Z","timestamp":1277473447000},"page":"353-359","source":"Crossref","is-referenced-by-count":6,"title":["Preparation and\n                    <i>In Vitro<\/i>\n                    Evaluation of\n                    <sup>131<\/sup>\n                    I-BmK CT as a Glioma-Targeted Agent"],"prefix":"10.1177","volume":"25","author":[{"given":"Jinhua","family":"Zhao","sequence":"first","affiliation":[{"name":"Shanghai Jiaotong University","place":["People's Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Qiao","sequence":"additional","affiliation":[{"name":"Shanghai Jiaotong University","place":["People's Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Jiaotong University","place":["People's Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Shao","sequence":"additional","affiliation":[{"name":"Tongji University","place":["People's Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,6,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00621-Q"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2388(199801\/02)14:1<79::AID-SSU10>3.0.CO;2-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.10083"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199604100-00013"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.10212"},{"key":"e_1_3_3_7_2","first-page":"4871","article-title":"Use of chlorotoxin for targeting of primary brain tumors","volume":"58","author":"Soroceanu L","year":"1998","unstructured":"Soroceanu L, , Gillespie Y, , Khazaeli MB et al. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res, 1998; 58:4871.","journal-title":"Cancer Res"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-0890-4"},{"key":"e_1_3_3_9_2","first-page":"580","article-title":"Imaging glioma extent with 131I-TM-601","volume":"46","author":"Hockaday DC","year":"2005","unstructured":"Hockaday DC, , Shen S, , Fiveash J et al. Imaging glioma extent with 131I-TM-601. J Nucl Med, 2005; 46:580.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4569"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(99)00181-6"},{"key":"e_1_3_3_12_2","first-page":"19","article-title":"Functional analysis of a gene encoding a chlorotoxin-like peptide derived from scorpion toxin","volume":"21","author":"Yang R","year":"2005","unstructured":"Yang R, , Peng F, , Liu H et al. Functional analysis of a gene encoding a chlorotoxin-like peptide derived from scorpion toxin. Chin J Biochem Mol Biol, 2005; 21:19.","journal-title":"Chin J Biochem Mol Biol"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2006.10.056"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910510103"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/10849780152389410"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2202"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-4205-6"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2009.0704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2009.0704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2009.0704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:12:33Z","timestamp":1777385553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2009.0704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1089\/cbr.2009.0704"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2009.0704","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}